NASDAQ:QUREUniqure Stock Price, Forecast & News

$66.76

+3.06 (+4.80 %)

(As of 05/26/2020 01:34 PM ET)

Add

Compare

Today's Range

$64.26

Now: $66.76▼

$67.96

50-Day Range

$45.55

MA: $57.70▼

$64.06

52-Week Range

$36.20

Now: $66.76▼

$82.49

Volume353,293 shs

Average Volume384,175 shs

Market Capitalization$2.96 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.31

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Uniqure has received a consensus rating of Buy. The company's average rating score is 2.92, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $86.00, Uniqure has a potential upside of 28.8% from its current price of $66.76.
Amount of Analyst Coverage
Uniqure has only been the subject of 3 research reports in the past 90 days.

2.9 Community Rank

Outperform Votes
Uniqure has received 575 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Uniqure has received 414 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Uniqure has received 58.14% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote “Outperform” if you believe QURE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Uniqure does not currently pay a dividend.
Dividend Growth
Uniqure does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Uniqure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,491,781.00 in company stock.
Percentage Held by Insiders
Only 2.66% of the stock of Uniqure is held by insiders.
Percentage Held by Institutions
78.57% of the stock of Uniqure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Uniqure are expected to decrease in the coming year, from ($3.22) to ($3.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Uniqure is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Uniqure is -22.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Uniqure has a P/B Ratio of 9.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.47 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:QURE

Previous Symbol

CUSIPN/A

CIK1590560

Webwww.uniqure.com

Phone31-20-240-6000

Debt

Debt-to-Equity Ratio0.12

Current Ratio12.89

Quick Ratio12.89

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$7.28 million

Price / Sales406.34

Cash FlowN/A

Price / Cash FlowN/A

Book Value$7.41 per share

Price / Book9.01

Profitability

EPS (Most Recent Fiscal Year)($3.11)

Net Income$-124,200,000.00

Net Margins-1,991.17%

Return on Equity-45.23%

Return on Assets-31.35%

Miscellaneous

Employees212

Outstanding Shares44,310,000

Market Cap$2.96 billion

Next Earnings Date8/3/2020 (Estimated)

OptionableOptionable

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Uniqure (NASDAQ:QURE) Frequently Asked Questions

How has Uniqure's stock been impacted by COVID-19 (Coronavirus)?

Uniqure's stock was trading at $47.54 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, QURE shares have increased by 40.4% and is now trading at $66.76. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Uniqure?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Uniqure.

When is Uniqure's next earnings date?

Uniqure is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Uniqure.

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) released its quarterly earnings data on Wednesday, April, 29th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.84) by $0.21. The biotechnology company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $1.76 million. Uniqure had a negative return on equity of 45.23% and a negative net margin of 1,991.17%. View Uniqure's earnings history.

What price target have analysts set for QURE?

13 equities research analysts have issued twelve-month price objectives for Uniqure's shares. Their forecasts range from $73.00 to $105.00. On average, they expect Uniqure's share price to reach $86.00 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View analysts' price targets for Uniqure.

What are Wall Street analysts saying about Uniqure stock?

Here are some recent quotes from research analysts about Uniqure stock:

1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (5/1/2020)
2. HC Wainwright analysts commented, "Enrollment completion in the HOPE-B registration study positions 12+month lead. We now anticipate data during 4Q20, with likely commercial launch during 4Q21, ahead of our prior 2H-2022 expectations. We continue to believe, AMT-061 remains the one-and-done therapy of choice based on: (1) the ability to successfully treat subjects with NAB’s to the peer construct; (2) low-levels of NABs to AAV5, which is a significant commercial differentiator, compelling centers to choose a therapy that could benefit the majority of patients i.e., >90% in case of AMT-061, over one with at least 40% exclusion criteria; and (3) no prophylactic steroids." (9/3/2019)
3. Chardan Capital analysts commented, "We continue our bullish QURE thesis (and affirm our $175 price target) ahead of what we see as among the most compelling 2020 catalysts in biotech:." (9/3/2019)

Has Uniqure been receiving favorable news coverage?

Media headlines about QURE stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Uniqure earned a media sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutUniqure.

Are investors shorting Uniqure?

Uniqure saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,560,000 shares, an increase of 10.4% from the April 30th total of 4,130,000 shares. Based on an average daily volume of 389,500 shares, the days-to-cover ratio is currently 11.7 days. Currently, 13.6% of the shares of the stock are sold short. View Uniqure's Current Options Chain.

Who are some of Uniqure's key competitors?

Some companies that are related to Uniqure include Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Mylan (MYL), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Myokardia (MYOK) and Forty Seven (FTSV). View all competitors.

What other stocks do shareholders of Uniqure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Uniqure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), GW Pharmaceuticals PLC- (GWPH), AbbVie (ABBV), Crispr Therapeutics (CRSP) and Square (SQ).

Who are Uniqure's key executives?

Uniqure's management team includes the following people:

Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Dr. Scott T. McMillan, Chief Operations Officer (Age 60)

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

Who are Uniqure's major shareholders?

Uniqure's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (6.61%), Redmile Group LLC (6.26%), Invesco Ltd. (4.63%), Orbimed Advisors LLC (2.22%), Janus Henderson Group PLC (1.64%) and BlackRock Inc. (1.52%). Company insiders that own Uniqure stock include Alexander Edward Kuta III, Christian Klemt, David Schaffer, Deventer Sander Van, Jack Kaye, Jeremy P Springhorn, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, Robert Gut, Scott T Mcmillan and Steven Zelenkofske. View institutional ownership trends for Uniqure.

Which institutional investors are selling Uniqure stock?

QURE stock was sold by a variety of institutional investors in the last quarter, including Cormorant Asset Management LP, Balyasny Asset Management LLC, JPMorgan Chase & Co., Two Sigma Advisers LP, Invesco Ltd., Orbimed Advisors LLC, Lord Abbett & CO. LLC, and Federated Hermes Inc.. Company insiders that have sold Uniqure company stock in the last year include Alexander Edward Kuta III, Christian Klemt, Deventer Sander Van, Jack Kaye, Matthew C Kapusta, Paula Soteropoulos, Philip Astley-Sparke, and Robert Gut. View insider buying and selling activity for Uniqure.

Which institutional investors are buying Uniqure stock?

QURE stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Redmile Group LLC, BlackRock Inc., RA Capital Management L.P., Deutsche Bank AG, Sphera Funds Management LTD., Assenagon Asset Management S.A., and Phoenix Holdings Ltd.. View insider buying and selling activity for Uniqure.

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $66.76.

How big of a company is Uniqure?

Uniqure has a market capitalization of $2.96 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Uniqure employs 212 workers across the globe.

What is Uniqure's official website?

The official website for Uniqure is www.uniqure.com.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]

This page was last updated on 5/26/2020 by MarketBeat.com Staff